Point of Care, Real-Time Urine Metabolomics Test to Diagnose Colorectal Cancers and Polyps in Low-and Middle-Income Countries
Key facts
- Who runs it
- Obafemi Awolowo University Teaching Hospital
- Where
- Nigeria1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Suspended
- People taking part
- 645 people enrolled
- Started
- 15 Aug 2022
- Ended
- 31 Mar 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Urine PolypDx machine Versus Colonoscopy
- Record updated
- 5 April 2024
- Why it stopped
- The urine POC device seems not to be promising in colorectal cancer screening
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Patients > 40 years of age with LGI bleeding for more than one week OR
- Patients who are high risk due to a family history of CRC (first-degree relative)
- Must be at most 10 years younger than when relative presented with CRC (For example, a patient with a relative diagnosed at age 40 with CRC will be eligible after age 30)
- Patients with a diagnosis of stage I-III CRC who have no evidence of disease
Who cannot take part
- Previous diagnosis, treatment, or surgery for any cancer other than CRC
- Inability to provide a urine sample no fewer than 3 days before colonoscopy
- Diagnosis of or suspected inflammatory bowel disease
- Age younger than 40 years with no family history of CRC
- criteria
- Patients who are unable to provide written informed consent
- Any significant medical comorbidities that the anesthesiologist or surgeon determines is a contraindication for colonoscopy in their facility
- Inability to fully complete the patient satisfaction survey tool
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Study description: the study is a clinical trial aimed at assessing the validity of a point-of-care tool developed for colorectal cancer screening using urine metabolites.
Read full original descriptionShow less
Objectives:
Primary Objective:
In the pilot phase, investigators will field test the POC device in Nigeria on 75 patients who are high-risk for CRC and then validate the urine metabolite signature using a large cohort of 645 patients at high risk for CRC and polyps. This will allow us to determine the sensitivity and specificity of this device and these signatures for CRC and polyps.
Endpoints: the endpoint will be the calculation of the validity (sensitivity and specificity) of the tool. Positive and negative predictive values will also be calculated.
Study population:
Patients > 40 years of age with LGI bleeding for more than one-week OR
* Patients who are high risk due to a family history of CRC (first-degree relative) * Must be at most 10 years younger than when relative presented with CRC (For example, a patient with a relative diagnosed at age 40 with CRC will be eligible after age 30) * Patients with a diagnosis of stage I-III CRC who have no evidence of disease Both males and females will be involved in the study
I. The study will evaluate the validity and acceptability of the POC biosensor device in Nigeria.
Description of sites/facilities enrolling participants: the study will be conducted at Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC) which hosts the head office of African Research Group for Oncology (ARGO). The study will also run concurrently at other ARGO collaborating sites. All the ARGO collaborating sites are tertiary health care facilities with experienced personnel to oversee the study. The pilot study will, however, take place in OAUTHC alone.
Study duration:
The accrual time for the validation study is 2.5 years. Participant Duration: the study will require initial one-time contact. Those that are positive during the screening with the POC biosensor device will be booked for colonoscopy. Hence, for participants with positive results to complete the study may require 2 weeks on average.
The 3 groups in the trial
- Patients low gastrointestinal tract bleedingExisting treatment, for comparison
Patients presenting in the surgical outpatients or emergency department with low gastrointestinal tract bleeding
Treatment: Urine PolypDx machine Versus Colonoscopy
- Participants who are high risk due to a family history of CRCExisting treatment, for comparison
First degree relatives of patients diagnosed with colorectal cancer
Treatment: Urine PolypDx machine Versus Colonoscopy
- Patients with a diagnosis of stage I-III CRC who have no evidence of diseaseExisting treatment, for comparison
Patients previously diagnosed of stage I-III CRC and managed in the hospital but are now having no evidence of disease
Treatment: Urine PolypDx machine Versus Colonoscopy
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 5 April 2024